CVS Health (CVS) insider trading
Insider activity, historical context and SEC filings · data through Nov 20, 2026
Some insider buying ($2.0M), but sales were much larger ($324M) over the same 12 months.
Label: Net selling · based on open-market trades (codes P and S), last 12 months. Not a rating or advice.- 90-day result for Prem S. Shah's $2.0M buy: in on Feb 4, 2027. See the 7- and 30-day results ↓
- Next earnings expected around Feb 3, 2027 (estimate from past release dates). Insiders usually trade in the weeks after results; past reactions ↓
Purchase Prem S. Shah, President bought 23,855 shares at $83.89 ($2.0M).
- Trade date
- Nov 6, 2026
- Disclosed to the SEC
- Nov 6, 2026
- Type
- Open-market purchase (code P)
Read the original SEC filing ↗All CVS insider trades ↓
✦ Read the full investigation of Prem S. Shah's $2.0M buy (Nov 6) →
Insiders have two business days to report a trade to the SEC, so filings (and our alerts) always come after the trade, never in real time.
CVS insider transactions (Form 4)
Open-market purchases and sales. 43 grants, option exercises and tax withholdings are not shown.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Nov 6SEC | Prem S. ShahPresidentFirst buy | Buy | 23,85588,516 held (+37%) | $83.89 | $2.0M | -4.6% | — |
| May 21SEC | Larry RobbinsDirector | Sell | 1,983,3876,213,412 held (−24%) | $94.45 | $187M | -15.3% | 83 |
| May 21SEC | Larry RobbinsDirector | Sell | 797,6285,415,633 held (−13%) | $93.48 | $74.6M | -14.4% | 83 |
| May 21SEC | Larry RobbinsDirector | Sell | 370,4624,824,799 held (−7%) | $93.45 | $34.6M | -14.4% | 83 |
| May 21SEC | Larry RobbinsDirector | Sell | 152,6915,262,942 held (−3%) | $94.81 | $14.5M | -15.6% | 83 |
| May 21SEC | Larry RobbinsDirector | Sell | 66,8815,196,061 held (−1%) | $95.67 | $6.4M | -16.4% | 83 |
| May 21SEC | Larry RobbinsDirector | Sell | 8005,195,261 held (−0%) | $96.28 | $77K | -16.9% | 83 |
| May 21SEC | Larry RobbinsDirector | Sell | 1516,213,261 held (−0%) | $95.18 | $14K | -15.9% | 83 |
| May 11SEC | Tilak MandadiEvp, Chief Exp & Tech Officer | Sell | 69,55110,133 held (−87%) | $89.58 | $6.2M | -10.7% | — |
| Jan 27SEC | Steven H. NelsonPresidentFirst buyNew positionBefore earnings | Buy | 24new position | $53.70 | $1K | +49.0% | — |
| Oct 14SEC | Heidi B. CapozziEvp And Chief People OfficerFirst buyStake +70% | Buy | 3585 held (+70%) | $56.85 | $2K | +40.8% | — |
| Oct 14SEC | Heidi B. CapozziEvp And Chief People OfficerFirst buyStake +700% | Buy | 3540 held (+700%) | $56.47 | $2K | +41.7% | — |
| Oct 14SEC | Heidi B. CapozziEvp And Chief People OfficerFirst buy | Buy | 1050 held (+25%) | $62.24 | $622 | +28.6% | — |
Play with CVS in the Research Lab
Pre-set to CVS's latest insider buy of $10K or more (Nov 6, 2026: Prem S. Shah, $2.0M). Tap to change anything.
Quick backtest: did buys like this beat the market?
Tap a setting to see how 6,290 past insider buys did.
- After CVS's buys7, 30 and 90 days later, losses included
- Find buys like this"insiders bought over $1M in the last 12 months"
- Compare CVS vs KODInsider buying and selling side by side
- CVS's board links9 companies share insiders with CVS
- Setup Odds for CVSEvery past buy like this one as a dot
- Play Insider Call5 real buys a day: guess which beat the market
Share price and insider trades
CVS Health insider trading at a glance (Nov 20, 2026): in the past 12 months, 1 insider bought $2.0M and 2 sold $324M of CVS stock on the open market; P/E 10.3 vs. a sector median of 25.0.
Setup Odds: how past setups like this did
CVS's latest insider buying (Nov 6, 2026) matched against every similar buy since 2020.
1 insider buying no CEO or CFO $1M+ stock down 0–20% in 3 months
67 of 144 past setups like this beat the S&P 500 over the next 90 days (47%), against 46% for all insider buys.
History, not a prediction: what happened next in similar past cases, measured from the day the last filing became public. Not investment advice.
By InsiderPrint Research Desk · Updated · Sources: SEC EDGAR Form 4 filings, FINRA short-sale volume · How we calculate this
CVS insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | $2.0M | 1 | — | 0 |
| Q3 2026 | — | 0 | — | 0 |
| Q2 2026 | — | 0 | $324M | 8 |
| Q1 2026 | — | 0 | — | 0 |
| Q4 2025 | — | 0 | — | 0 |
| Q3 2025 | — | 0 | — | 0 |
| Q2 2025 | — | 0 | — | 0 |
| Q1 2025 | $1K | 1 | — | 0 |
Valuation, profit and volume
Watchlist score 55/100 · selling pressure highSource: Yahoo Finance, as of Nov 16, 2026. Volume and paper profit use daily closing prices.
Summary
Over the past 12 months, 1 CVS Health insider reported open-market purchases totaling $2.0M, while 2 insiders reported sales totaling $324M. Among insiders with enough purchase history to measure, Larry Robbins (Director) has the highest Insider Score at 83. 0 of 8 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
CVS earnings: how the stock reacted
Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.
| Release | 15 days before | Insiders, 30 days before | Reaction (2 days) | Next 30 days |
|---|---|---|---|---|
| Nov 4, 2026 | -0.7% | None | -11.0%S&P -2.8% | pending |
| Aug 5, 2026 | -2.4% | None | -7.9%S&P -0.4% | +0.5% |
| May 6, 2026 | +6.3% | None | +8.3%S&P +1.1% | +9.8% |
| Feb 10, 2026 | -8.7% | None | +1.6%S&P -0.3% | -1.2% |
| Oct 29, 2025 | +5.7% | None | -6.7%S&P -1.1% | +4.8% |
| Jul 31, 2025 | -1.5% | None | +0.3%S&P -2.0% | +17.1% |
| May 1, 2025 | -2.2% | None | +1.1%S&P +2.2% | -5.1% |
| Feb 12, 2025 | -2.1% | None | +20.7%S&P +0.7% | -1.0% |
Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.
CVS short selling
Daily short-sale volume as a share of trading volume (FINRA), with the 20-day average.
This is short volume from off-exchange trades, not short interest. It includes market makers' routine hedging, so 40–50% is normal; what stands out is a ratio well above the stock's own average. Insiders buying while shorts pile in →
Members of Congress who traded CVS
From STOCK Act disclosures. Reported up to 45 days after the trade, in dollar ranges.
| Member | Trade | Traded | Reported | Since trade |
|---|---|---|---|---|
| Thomas H TubervilleSenate | Sold $1,001 - $15,000 | Aug 26, 2024 | Aug 5, 2026 | +47.1% |
| Alan ArmstrongSenate | Bought $1,001 - $15,000 | Mar 27, 2026 | Jul 21, 2026 | +15.9% |
| John BoozmanSenate | Bought $1,001 - $15,000 | Jan 29, 2026 | Feb 15, 2026 | +9.1% |
CVS stock news and SEC filings
Recent 8-K filings and headlines. Tone is scored from the headline wording; “Policy” marks regulatory, trade or government topics.
What happened after CVS insiders bought
Each open-market purchase, measured from the day the filing became public, next to the S&P 500 over the same days. Losses included; "pending" means the days haven't passed yet.
| Filed | Insider | Bought | 7 days | 30 days | 90 days |
|---|---|---|---|---|---|
| Nov 6, 2026 | Prem S. ShahPresident | $2.0M | +6.6%+4.0% vs S&P | pending | pending |
Insiders at CVS Health
| Insider | Bought | Sold | Last filing | Past buys beat S&P | Score |
|---|---|---|---|---|---|
| Larry RobbinsDirector | — | $317M | May 21, 2026 | 2 of 4 | 83 |
| Tilak MandadiEvp, Chief Exp & Tech Officer | — | $6.2M | May 11, 2026 | — | — |
| Prem S. ShahPresident | $2.0M | — | Nov 6, 2026 | — | — |
| Heidi B. CapozziEvp And Chief People Officer | $5K | — | Apr 2, 2026 | — | — |
| Steven H. NelsonPresident | $1K | — | Apr 2, 2026 | — | — |
| James David ClarkSvp, Cont & Chief Acct Officer | — | — | Jun 29, 2026 | — | — |
| Amy Compton-PhillipsEvp, Chief Medical Officer | — | — | Jun 1, 2026 | — | — |
| Brian NewmanCFO | — | — | Jun 1, 2026 | — | — |
| Fernando AguirreDirector | — | — | May 22, 2026 | — | — |
| Jeffrey R. BalserDirector | — | — | May 15, 2026 | — | — |
| C. David Brown IIDirector | — | — | May 15, 2026 | — | — |
| Guy P. SansoneDirector | — | — | May 15, 2026 | 1 of 1 | — |
| Leslie V. NorwalkDirector | — | — | May 15, 2026 | — | — |
| J. Scott KirbyDirector | — | — | May 15, 2026 | — | — |
| J. David JoynerCEO, President | — | — | Apr 2, 2026 | — | — |
| Samrat S. KhichiGeneral Counsel | — | — | Apr 2, 2026 | — | — |
| John E. GallinaDirector | — | — | Mar 20, 2026 | — | — |
| Roger N. FarahDirector | — | — | Dec 2, 2025 | — | — |
| Douglas H. ShulmanDirector | — | — | Nov 21, 2025 | — | — |
| Anne A. FinucaneDirector | — | — | Nov 21, 2025 | — | — |
Board links: companies that share insiders with CVS
Directors and executives who filed Form 4s for CVS and another company in the last 12 months.
- BFLYButterfly Network Larry Robbins Director here · Director at BFLY · latest filing Aug 17, 2026
- CLColgate-Palmolive Brian Newman CFO here · Director at CL · latest filing Oct 2, 2026
- GMEDGlobus Medical Leslie V. Norwalk Director here · Director at GMED · latest filing May 15, 2026
- NBIXNeurocrine Biosciences Leslie V. Norwalk Director here · Director at NBIX · latest filing Jul 30, 2026
- OMFOneMain Holdings Douglas H. Shulman Director here · CEO, President at OMF · latest filing Jan 2, 2026
- PGRProgressive Roger N. Farah Director here · Director at PGR · latest filing May 12, 2026
- SYFSynchrony Financial Fernando Aguirre Director here · Director at SYF · latest filing Nov 18, 2026
- UALUnited Airlines J. Scott Kirby Director here · CEO at UAL · latest filing Nov 10, 2026
- WSMWilliams-Sonoma Anne A. Finucane Director here · Director at WSM · latest filing Oct 16, 2026
Insider activity at other Health Care companies
Same sector, ranked by insider buying in the last 90 days.
CVS stock: common questions
Are CVS Health insiders buying CVS stock?
In the past 12 months, 1 insider reported open-market purchases of CVS worth $2.0M. The latest was President Prem S Shah bought $2.0M of CVS at $83.89 — first open-market purchase in our records; raises the stake by 37%.
Are CVS Health insiders selling CVS stock?
2 insiders reported sales worth $324M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is CVS's P/E ratio?
CVS trades at about 10.3 times trailing earnings, compared with a median of 25.0 for the Health Care sector.
What is CVS's 52-week range?
Over the past year CVS has traded between $69.04 and $109.92. It last closed at $80.02 on Nov 19, 2026.